journal article·2025-01-10Open access

Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections

Vaibhav Pathak, Hak-Kim Chan, Qi Tony Zhou

KONA Powder and Particle Journal· Volume 42· Issue 0

Abstract

Rapid development of antibiotic resistance in pathogenic bacteria and a decline in the pharmaceutical development of new antibiotics are pushing the research community to explore alternative antimicrobials that can replace or complement antibiotics. Bacteriophages (or, phages) are naturally occurring viruses that can kill bacteria with high specificity and can evolve to target resistant bacteria. Phages have been historically employed as antimicrobial agents, but they were overshadowed by the emergence of antibiotics. With a renewed focus on phages, it is important to study their clinical efficacy, safety, and formulation. Pulmonary infections have a large burden of global morbidity and frequently involve multidrug-resistant pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae, Mycobacterium tuberculosis, and Pseudomonas aeruginosa. Therefore, this can be an important area of application of phages. Dry powder inhalers can be an effective strategy to deliver phages to the lungs because they are easy-to-use, portable, and capable of delivering a higher lung dose than oral or intravenous route. They also have longer shelf life and lower cold storage requirements than solutions. Therefore, the aim of the current review is to summarize recent findings on bacteriophage dry powder formulations, particularly focusing on the effect of various excipients and manufacturing factors on phage titer preservation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Bacteriophages and microbial interactions · Protein purification and stability

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, USA

Advanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia

References (65)

Show source-provided references
1. Abedon S.T., Phage therapy of pulmonary infections, Bacteriophage, 5 (2015) e1020260. https://doi.org/10.1080/21597081.2015.102026010.1080/21597081.2015.1020260 ↗
2. Ács N., Gambino M., Brøndsted L., Bacteriophage enumeration and detection methods, Frontiers in Microbiology, 11 (2020) 594868. https://doi.org/10.3389/fmicb.2020.59486810.3389/fmicb.2020.594868 ↗
3. Arte K.S., Tower C.W., Mutukuri T.T., Chen Y., Patel S.M., Munson E.J., Zhou Q., Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation, International Journal of Pharmaceutics, 650 (2024) 123698. https://doi.org/10.1016/j.ijpharm.2023.12369810.1016/j.ijpharm.2023.123698 ↗
4. Bartlett J.G., Gilbert D.N., Spellberg B., Seven ways to preserve the miracle of antibiotics, Clinical Infectious Diseases, 56 (2013) 1445–1450. https://doi.org/10.1093/cid/cit07010.1093/cid/cit070 ↗
5. Bhadoriya P., Sharma R., Mehrotra R., Kaur S., Srivastava I., Jain M., Kaushik P., A review on re-emerging bacteriophage therapy in the era of XDR, Biocell, 47 (2023) 1915–1930. https://doi.org/10.32604/biocell.2023.02956410.32604/biocell.2023.029564 ↗
6. Bodier-Montagutelli E., Morello E., L’Hostis G., Guillon A., Dalloneau E., Respaud R., Pallaoro N., Blois H., Vecellio L., Gabard J., Heuzé-Vourc’h N., Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections, Expert Opinion on Drug Delivery, 14 (2017) 959–972. https://doi.org/10.1080/17425247.2017.125232910.1080/17425247.2017.1252329 ↗
7. Cao F., Wang X., Wang L., Li Z., Che J., Wang L., Li X., Cao Z., Zhang J., Jin L., Xu Y., Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice, BioMed Research International, 1 (2015) 752930. https://doi.org/10.1155/2015/752930
8. Carrigy N.B., Liang L., Wang H., Kariuki S., Nagel T.E., Connerton I.F., Vehring R., Spray-dried anti-Campylobacter bacteriophage CP30A powder suitable for global distribution without cold chain infrastructure, International journal of pharmaceutics, 569 (2019) 118601. https://doi.org/10.1016/j.ijpharm.2019.11860110.1016/j.ijpharm.2019.118601 ↗
9. Carrigy N.B., Liang L., Wang H., Kariuki S., Nagel T.E., Connerton I.F., Vehring R., Trileucine and pullulan improve anti-campylobacter bacteriophage stability in engineered spray-dried microparticles, Annals of Biomedical Engineering, 48 (2020) 1169–1180. https://doi.org/10.1007/s10439-019-02435-610.1007/s10439-019-02435-6 ↗
10. Chan B.K., Turner P.E., Kim S., Mojibian H.R., Elefteriades J.A., Narayan D., Phage treatment of an aortic graft infected with Pseudomonas aeruginosa, Evolution, Medicine, and Public Health, 2018 (2018) 60–66. https://doi.org/10.1093/emph/eoy00510.1093/emph/eoy005 ↗
11. Chang L., Pikal M.J., Mechanisms of protein stabilization in the solid state, Journal of Pharmaceutical Sciences, 98 (2009) 2886–2908. https://doi.org/10.1002/jps.2182510.1002/jps.21825 ↗
12. Chang R.Y., Wong J., Mathai A., Morales S., Kutter E., Britton W., Li J., Chan H.-K., Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection, European Journal of Pharmaceutics and Biopharmaceutics, 121 (2017) 1–13. https://doi.org/10.1016/j.ejpb.2017.09.00210.1016/j.ejpb.2017.09.002 ↗
13. Chang R.Y.K., Chen K., Wang J., Wallin M., Britton W., Morales S., Kutter E., Li J., Chan H.-K., Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation, Antimicrobial Agents and Chemotherapy, 62 (2018). https://doi.org/10.1128/aac.01714-1710.1128/AAC.01714-17 ↗
14. Chang R.Y.K., Kwok P.C.L., Khanal D., Morales S., Kutter E., Li J., Chan H.-K., Inhalable bacteriophage powders: glass transition temperature and bioactivity stabilization, Bioengineering & Translational Medicine, 5 (2020) e10159. https://doi.org/10.1002/btm2.1015910.1002/btm2.10159 ↗
15. Chen Y., Ling J., Li M., Su Y., Arte K.S., Mutukuri T.T., Taylor L.S., Munson E.J., Topp E.M., Zhou Q.T., Understanding the impact of protein–excipient interactions on physical stability of spray-dried protein solids, Molecular Pharmaceutics, 18 (2021) 2657–2668. https://doi.org/10.1021/acs.molpharmaceut.1c0018910.1021/acs.molpharmaceut.1c00189 ↗
16. Cleland J.L., Lam X., Kendrick B., Yang J., Yang T.h., Overcashier D., Brooks D., Hsu C., Carpenter J.F., A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody, Journal of Pharmaceutical Sciences, 90 (2001) 310–321. https://doi.org/10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R ↗
17. Comeau A.M., Tétart F., Trojet S.N., Prère M.-F., Krisch H.M., Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth, PLOS ONE, 2 (2007) e799. https://doi.org/10.1371/journal.pone.000079910.1371/journal.pone.0000799 ↗
18. Debarbieux L., Leduc D., Maura D., Morello E., Criscuolo A., Grossi O., Balloy V., Touqui L., Bacteriophages can treat and prevent pseudomonas aeruginosa lung infections, The Journal of Infectious Diseases, 201 (2010) 1096–1104. https://doi.org/10.1086/65113510.1086/651135 ↗
19. Doub J., Risk of bacteriophage therapeutics to transfer genetic material and contain contaminants beyond endotoxins with clinically relevant mitigation strategies, Infection and Drug Resistance, 14 (2021) 5629–5637. https://doi.org/10.2147/IDR.S34126510.2147/IDR.S341265 ↗
20. Golshahi L., Lynch K.H., Dennis J.J., Finlay W.H., In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis, Journal of Applied Microbiology, 110 (2011) 106–117. https://doi.org/10.1111/j.1365-2672.2010.04863.x10.1111/j.1365-2672.2010.04863.x ↗
21. Gordillo Altamirano F.L., Barr J.J., Unlocking the next generation of phage therapy: the key is in the receptors, Current Opinion in Biotechnology, 68 (2021) 115–123. https://doi.org/10.1016/j.copbio.2020.10.00210.1016/j.copbio.2020.10.002 ↗
22. Gould I.M., Bal A.M., New antibiotic agents in the pipeline and how they can help overcome microbial resistance, Virulence, 4 (2013) 185–191. https://doi.org/10.4161/viru.2250710.4161/viru.22507 ↗
23. Grasmeijer N., Stankovic M., de Waard H., Frijlink H.W., Hinrichs W.L., Unraveling protein stabilization mechanisms: vitrification and water replacement in a glass transition temperature controlled system, Biochim Biophys Acta, 1834 (2013) 763–769. https://doi.org/10.1016/j.bbapap.2013.01.02010.1016/j.bbapap.2013.01.020 ↗
24. Hauser A.R., Jain M., Bar-Meir M., McColley S.A., Clinical significance of microbial infection and adaptation in cystic fibrosis, Clinical Microbiology Reviews, 24 (2011) 29–70. https://doi.org/10.1128/cmr.00036-1010.1128/CMR.00036-10 ↗
25. Hoppentocht M., Dry powder inhalation of antibiotics: a promising approach for treatment of infectious diseases, doctoral thesis, University of Groningen, 2016, ISBN: 978-94-90791-44-5.
26. Hoyle N., Zhvaniya P., Balarjishvili N., Bolkvadze D., Nadareishvili L., Nizharadze D., Wittmann J., Rohde C., Kutateladze M., Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report, Research in Microbiology, 169 (2018) 540–542. https://doi.org/10.1016/j.resmic.2018.05.00110.1016/j.resmic.2018.05.001 ↗
27. Kamal F., Dennis J.J., Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity, Applied and Environmental Microbiology, 81 (2015) 1132–1138. https://doi.org/10.1128/AEM.02850-1410.1128/AEM.02850-14 ↗
28. Ke W.-R., Chang R.Y.K., Chan H.-K., Engineering the right formulation for enhanced drug delivery, Advanced Drug Delivery Reviews, 191 (2022) 114561. https://doi.org/10.1016/j.addr.2022.11456110.1016/j.addr.2022.114561 ↗
29. Kortright K.E., Chan B.K., Koff J.L., Turner P.E., Phage therapy: a renewed approach to combat antibiotic-resistant bacteria, Cell Host & Microbe, 25 (2019) 219–232. https://doi.org/10.1016/j.chom.2019.01.01410.1016/j.chom.2019.01.014 ↗
30. Kosznik-Kwaśnicka K., Kaźmierczak N., Piechowicz L., Activity of phage–lactoferrin mixture against multi drug resistant staphylococcus aureus biofilms, Antibiotics, 11 (2022) 1256. https://doi.org/10.3390/antibiotics1109125610.3390/antibiotics11091256 ↗
31. Kwok P.C.L., Chan H.-K., Delivery of inhalation drugs to children for asthma and other respiratory diseases, Advanced Drug Delivery Reviews, 73 (2014) 83–88. https://doi.org/10.1016/j.addr.2013.11.00710.1016/j.addr.2013.11.007 ↗
32. LeClair D.A., Cranston E.D., Xing Z., Thompson M.R., Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying, International Journal of Pharmaceutics, 506 (2016) 289–301. https://doi.org/10.1016/j.ijpharm.2016.04.06710.1016/j.ijpharm.2016.04.067 ↗
33. Leung S.S.Y., Parumasivam T., Gao F.G., Carrigy N.B., Vehring R., Finlay W.H., Morales S., Britton W.J., Kutter E., Chan H.-K., Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections, Pharmaceutical Research, 33 (2016) 1486–1496. https://doi.org/10.1007/s11095-016-1892-610.1007/s11095-016-1892-6 ↗
34. Leung S.S.Y., Parumasivam T., Gao F.G., Carter E.A., Carrigy N.B., Vehring R., Finlay W.H., Morales S., Britton W.J., Kutter E., Chan H.-K., Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders, International Journal of Pharmaceutics, 521 (2017) 141–149. https://doi.org/10.1016/j.ijpharm.2017.01.06010.1016/j.ijpharm.2017.01.060 ↗
35. Leung S.S.Y., Parumasivam T., Nguyen A., Gengenbach T., Carter E.A., Carrigy N.B., Wang H., Vehring R., Finlay W.H., Morales S., Britton W.J., Kutter E., Chan H.-K., Effect of storage temperature on the stability of spray dried bacteriophage powders, European Journal of Pharmaceutics and Biopharmaceutics, 127 (2018) 213–222. https://doi.org/10.1016/j.ejpb.2018.02.03310.1016/j.ejpb.2018.02.033 ↗
36. Li L., Leung S.S.Y., Gengenbach T., Yu J., Gao G., Tang P., Zhou Q., Chan H.-K., Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation, International Journal of Pharmaceutics, 530 (2017) 30–39. https://doi.org/10.1016/j.ijpharm.2017.07.03310.1016/j.ijpharm.2017.07.033 ↗
37. Li L., Sun S., Parumasivam T., Denman J.A., Gengenbach T., Tang P., Mao S., Chan H.-K., L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders, European Journal of Pharmaceutics and Biopharmaceutics, 102 (2016) 132–141. https://doi.org/10.1016/j.ejpb.2016.02.01010.1016/j.ejpb.2016.02.010 ↗
38. Li M., Chang R.Y.K., Lin Y., Morales S., Kutter E., Chan H.-K., Phage cocktail powder for Pseudomonas aeruginosa respiratory infections, International Journal of Pharmaceutics, 596 (2021) 120200. https://doi.org/10.1016/j.ijpharm.2021.12020010.1016/j.ijpharm.2021.120200 ↗
39. Livermore D.M., Multiple mechanisms of antimicrobial resistance in pseudomonas aeruginosa: our worst nightmare?, Clinical Infectious Diseases, 34 (2002) 634–640. https://doi.org/10.1086/33878210.1086/338782 ↗
40. Livermore D.M., The threat from the pink corner, Annals of Medicine, 35 (2003) 226–234. https://doi.org/10.1080/0785389031000160910.1080/07853890310001609 ↗
41. Loc-Carrillo C., Abedon S.T., Pros and cons of phage therapy, Bacteriophage, 1 (2011) 111–114. https://doi.org/10.4161/bact.1.2.1459010.4161/bact.1.2.14590 ↗
42. Ly A., Carrigy N.B., Wang H., Harrison M., Sauvageau D., Martin A.R., Vehring R., Finlay W.H., Atmospheric spray freeze drying of sugar solution with phage D29, Frontiers in Microbiology, 10 (2019) 488. https://doi.org/10.3389/fmicb.2019.0048810.3389/fmicb.2019.00488 ↗
43. Matinkhoo S., Lynch K.H., Dennis J.J., Finlay W.H., Vehring R., Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections, Journal of Pharmaceutical Sciences, 100 (2011) 5197–5205. https://doi.org/10.1002/jps.2271510.1002/jps.22715 ↗
44. Merabishvili M., Vervaet C., Pirnay J.-P., De Vos D., Verbeken G., Mast J., Chanishvili N., Vaneechoutte M., Stability of staphylococcus aureus phage ISP after freeze-drying (lyophilization), PLOS ONE, 8 (2013) e68797. https://doi.org/10.1371/journal.pone.006879710.1371/journal.pone.0068797 ↗
45. Patton J.S., Byron P.R., Inhaling medicines: delivering drugs to the body through the lungs, Nature Reviews Drug Discovery, 6 (2007) 67–74. https://doi.org/10.1038/nrd215310.1038/nrd2153 ↗
46. Roach D.R., Leung C.Y., Henry M., Morello E., Singh D., Di Santo J.P., Weitz J.S., Debarbieux L., Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen, Cell Host & Microbe, 22 (2017) 38–47.e34. https://doi.org/10.1016/j.chom.2017.06.01810.1016/j.chom.2017.06.018 ↗
47. Rossolini G.M., Arena F., Pecile P., Pollini S., Update on the antibiotic resistance crisis, Current Opinion in Pharmacology, 18 (2014) 56–60. https://doi.org/10.1016/j.coph.2014.09.00610.1016/j.coph.2014.09.006 ↗
48. Ruest M.K., Supina B.S.I., Dennis J.J., Bacteriophage steering of Burkholderia cenocepacia toward reduced virulence and increased antibiotic sensitivity, Journal of Bacteriology, 205 (2023) e00196–00123. https://doi.org/10.1128/jb.00196-2310.1128/jb.00196-23 ↗
49. Ryan E.M., Alkawareek M.Y., Donnelly R.F., Gilmore B.F., Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro, FEMS Immunology & Medical Microbiology, 65 (2012) 395–398. https://doi.org/10.1111/j.1574-695X.2012.00977.x10.1111/j.1574-695X.2012.00977.x ↗
50. Santana H., Sotolongo J., González Y., Hernández G., Chinea G., Gerónimo H., Amarantes O., Beldarraín A., Páez R., Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying, Biologicals, 42 (2014) 322–333. https://doi.org/10.1016/j.biologicals.2014.07.00510.1016/j.biologicals.2014.07.005 ↗
51. Semler D.D., Goudie A.D., Finlay W.H., Dennis J.J., Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections, Antimicrobial Agents and Chemotherapy, 58 (2014) 4005–4013. https://doi.org/10.1128/aac.02388-1310.1128/AAC.02388-13 ↗
52. Scoffone V.C., Barbieri G., Irudal S., Trespidi G., Buroni S., New antimicrobial strategies to treat multi-drug resistant infections caused by gram-negatives in cystic fibrosis, Antibiotics, 13 (2024) 71. https://doi.org/10.3390/antibiotics1301007110.3390/antibiotics13010071 ↗
53. Tagliaferri T.L., Jansen M., Horz H.-P., Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy, Frontiers in Cellular and Infection Microbiology, 9 (2019) 22. https://doi.org/10.3389/fcimb.2019.0002210.3389/fcimb.2019.00022 ↗
54. Torres-Barceló C., Hochberg M.E., Evolutionary rationale for phages as complements of antibiotics, Trends in Microbiology, 24 (2016) 249–256. https://doi.org/10.1016/j.tim.2015.12.01110.1016/j.tim.2015.12.011 ↗
55. Uchiyama J., Shigehisa R., Nasukawa T., Mizukami K., Takemura-Uchiyama I., Ujihara T., Murakami H., Imanishi I., Nishifuji K., Sakaguchi M., Matsuzaki S., Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa, Archives of Virology, 163 (2018) 1941–1948. https://doi.org/10.1007/s00705-018-3811-010.1007/s00705-018-3811-0 ↗
56. Vandenheuvel D., Meeus J., Lavigne R., Van den Mooter G., Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix, International Journal of Pharmaceutics, 472 (2014) 202–205. https://doi.org/10.1016/j.ijpharm.2014.06.02610.1016/j.ijpharm.2014.06.026 ↗
57. Vandenheuvel D., Singh A., Vandersteegen K., Klumpp J., Lavigne R., Van den Mooter G., Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections, European Journal of Pharmaceutics and Biopharmaceutics, 84 (2013) 578–582. https://doi.org/10.1016/j.ejpb.2012.12.02210.1016/j.ejpb.2012.12.022 ↗
58. Ventola C.L., The antibiotic resistance crisis: part 1: causes and threats, Pharmacy and Therapeutics, 40 (2015) 277–283. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/
59. Walters R.H., Bhatnagar B., Tchessalov S., Izutsu K.-I., Tsumoto K., Ohtake S., Next generation drying technologies for pharmaceutical applications, Journal of Pharmaceutical Sciences, 103 (2014) 2673–2695. https://doi.org/10.1002/jps.2399810.1002/jps.23998 ↗
60. Wang W., Lyophilization and development of solid protein pharmaceuticals, International Journal of Pharmaceutics, 203 (2000) 1–60. https://doi.org/10.1016/S0378-5173(00)00423-310.1016/S0378-5173(00)00423-3 ↗
61. Yan W., He R., Tang X., Tian B., Liu Y., Tong Y., To K.K.W., Leung S.S.Y., The influence of formulation components and environmental humidity on spray-dried phage powders for treatment of respiratory infections caused by Acinetobacter baumannii, Pharmaceutics, 13 (2021) 1162. https://doi.org/10.3390/pharmaceutics1308116210.3390/pharmaceutics13081162 ↗
62. Yang M., Du C., Gong P., Xia F., Sun C., Feng X., Lei L., Song J., Zhang L., Wang B., Xiao F., Yan X., Cui Z., Li X., Gu J., et al., Therapeutic effect of the YH6 phage in a murine hemorrhagic pneumonia model, Research in Microbiology, 166 (2015) 633–643. https://doi.org/10.1016/j.resmic.2015.07.00810.1016/j.resmic.2015.07.008 ↗
63. Zarzosa-Moreno D., Avalos-Gómez C., Ramírez-Texcalco L.S., Torres-López E., Ramírez-Mondragón R., Hernández-Ramírez J.O., Serrano-Luna J., de la Garza M., Lactoferrin and its derived peptides: an alternative for combating virulence mechanisms developed by pathogens, Molecules, 25 (2020) 5763. https://doi.org/10.3390/molecules2524576310.3390/molecules25245763 ↗
64. Zhou Q., Tang P., Leung S.S.Y., Chan J.G.Y., Chan H.-K., Emerging inhalation aerosol devices and strategies: where are we headed?, Advanced Drug Delivery Reviews, 75 (2014) 3–17. https://doi.org/10.1016/j.addr.2014.03.00610.1016/j.addr.2014.03.006 ↗
65. Zimecki M., Artym J., Kocieba M., Weber-Dabrowska B., Lusiak-Szelachowska M., Górski A., The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice, Postepy Hig Med Dosw (Online), 62 (2008) 42–46. https://pubmed.ncbi.nlm.nih.gov/18268472/